Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gattringer, T; Enzinger, C; Pinter, D; Fandler-Höfler, S; Kneihsl, M; Haidegger, M; Eppinger, S; Demjaha, R; Buchmann, A; Jerkovic, A; Schmidt, R; Khalil, M.
Serum glial fibrillary acidic protein is sensitive to acute but not chronic tissue damage in cerebral small vessel disease.
J Neurol. 2023; 270(1):320-327
Doi: 10.1007/s00415-022-11358-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Gattringer Thomas
- Co-Autor*innen der Med Uni Graz
- Buchmann Arabella
- Demjaha Rina
- Enzinger Christian
- Eppinger Sebastian
- Fandler-Höfler Simon
- Haidegger Melanie
- Khalil Michael
- Kneihsl Markus
- Pinter Daniela Theresia
- Schmidt Reinhold
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Serum glial fibrillary acidic protein (sGFAP) has been proposed as a biomarker in various neurological diseases but has not yet been systematically investigated in patients with cerebral small vessel disease (CSVD). We explored whether sGFAP levels are increased in stroke patients with MRI-confirmed recent small subcortical infarcts (RSSI) and analyzed the subsequent course and determinants of sGFAP longitudinally. METHODS: In a prospectively-collected cohort of stroke patients with a single RSSI (n = 101, mean age: 61 years, 73% men), we analyzed brain MRI and sGFAP using a SIMOA assay at baseline and at 3- and 15-months post-stroke. Community-dwelling age- and sex-matched individuals (n = 51) served as controls. RESULTS: RSSI patients had higher baseline sGFAP levels compared to controls (median: 187.4 vs. 118.3 pg/ml, p < 0.001), with no influence of the time from stroke symptom onset to baseline blood sampling (median 5 days, range 1-13). At the 3- and 15-months follow-up, sGFAP returned to control levels. While baseline sGFAP correlated with larger infarct size (rs = 0.28, p = 0.01), neither baseline nor follow-up sGFAP levels were associated with chronic CSVD-related lesions (white matter hyperintensities, lacunes, microbleeds) after adjusting for age, sex and hypertension. Furthermore, sGFAP levels did not relate to the occurrence of new vascular brain lesions on follow-up MRI. CONCLUSIONS: sGFAP is increased in patients with CSVD-related stroke and correlates with the size of the RSSI. However, sGFAP levels were not related to chronic neuroimaging features or progression of CSVD, suggesting that sGFAP is sensitive to acute but not chronic cerebrovascular tissue changes in this condition.
- Find related publications in this database (using NLM MeSH Indexing)
- Male - administration & dosage
- Humans - administration & dosage
- Middle Aged - administration & dosage
- Female - administration & dosage
- Stroke, Lacunar - diagnostic imaging
- Glial Fibrillary Acidic Protein - administration & dosage
- Cerebral Small Vessel Diseases - complications, diagnostic imaging
- Brain - diagnostic imaging, pathology
- Stroke - complications
- Magnetic Resonance Imaging - methods
- Find related publications in this database (Keywords)
- Glial fibrillary acidic protein
- GFAP
- Stroke
- Lacunar stroke
- Cerebral small vessel disease
- Recent small subcortical infarcts